An Update on the Outcomes of Patients Treated with Urolift for Benign Prostatic Hyperplasia

Justin Loloi,1 Nathan Feiertag,2 Kripali Gautam,2 Pedro Maria1 1Department of Urology, Montefiore Medical Center, Bronx, NY, USA; 2Albert Einstein College of Medicine, Bronx, NY, USACorrespondence: Pedro MariaDepartment of Urology, Montefiore Medical Center, Bronx, NY, 10467, USATel +1 718 920 4531Email [email protected]: Benign prostatic hyperplasia (BPH) is a ubiquitous urologic disease affecting aging men. Patients often experience bothersome lower urinary tract symptoms (LUTS) that warrant urologic evaluation and management. Routinely, patients are initially treated with medical therapies with the goal of both relaxing the bladder neck and shrinking the prostate in order to relieve obstruction secondary to prostatic enlargement. Transurethral resection of the prostate (TURP) serves as a first-line surgical intervention in those who fail medical therapy. Recently, novel minimally invasive surgical techniques for BPH management have emerged. Of these, prostatic urethral lift (PUL or Urolift) has gained attention given its presumed effectiveness and minimal risk of sexual side effects when compared to the standard TURP. The purpose of this review is to describe past and current trends in the implementation of PUL for BPH and to highlight important outcomes.Keywords: benign, prostate, minimally-invasive, urethral, urinary, sexua

Hip and Knee Section, Treatment, Debridement and Retention of Implant: Proceedings of International Consensus on Orthopedic Infections

acute periprosthetic joint infectio